Showing 5111-5120 of 10416 results for "".
- Nathalie Daste Named LEO Pharma’s New Executive Vice President of Global People and Corporate Affairshttps://practicaldermatology.com/news/nathalie-daste-named-leo-pharmas-new-executive-vice-president-of-global-people-and-corporate-affairs/2461964/Nathalie Daste is LEO Pharma’s new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023. In her new role, Ms. Daste will head LEO Pharma’s Global People function as well as Corporate Affa
- Burt's Bees Products Improve Redness, Pigmentation, and Reduce Acne-related PIHhttps://practicaldermatology.com/news/burts-bees-products-improve-redness-pigmentation-and-reduce-acne-related-pih/2461624/Burt’s Bees topical bakuchiol-containing sunscreen treats redness and pigmentation of photodamaged facial skin. What’s more, a cream containing Glycyrrhiza glabra (licorice root), Curcuma longa (turmeric root), and Terminalia chebula improves&n
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pha
- Congrats: Dr. Paul Bergstresser Receives ASA’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-paul-bergstresser-receives-asas-david-martin-carter-mentor-award/2460401/Dr. Paul Bergstresser of UT Southwestern Medical Center in Dallas, Texas is the recipient of the American Skin Association’s (ASA) 2020 David Martin Carter Mentor Award Since 1989, ASA's David Martin Carter Mentor Award has honored members of the derma
- Hair Up Top: Restoration Names New CFOhttps://practicaldermatology.com/news/hair-up-top-restoration-names-new-cfo/2457955/Restoration Robotics, Inc. will have a new Chief Financial Officer next year. Industry veteran Mark L. Hair will fill the post effective January 5, 2018. Mr. Hair brings with him over 20 years of executive management, financial advisory, consulting, and public company exp
- Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenationhttps://practicaldermatology.com/news/dr-michelle-henry-highlights-noninvasive-periorbital-rejuvenation/2483904/Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, s
- New IL-13/IL-31R Bispecific Antibody Data Presented at EAACIhttps://practicaldermatology.com/news/New-IL-13-IL-31R-Bispecific-Antibody-Data-Presented-EAACI/2475170/A new IL-13/IL-31R bispecific antibody demonstrated ability to simultaneously suppress the inflammatory and pruritogenic pathways in atopic dermatitis (AD), according to preclinical study data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, S
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s
- FDA Approves Up To 3 Tubes of Ameluz Topical Gel, 10% In 1 Treatmenthttps://practicaldermatology.com/news/fda-approves-3-tubes-ameluz-topical-gel-10-1-treatment/2468368/The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to increase the maximally approved dosage from one to three tubes of Biofrontera Inc.’s Ameluz® per treatment, the company announced. Biofrontera Inc. said in a press release that the approval
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor